Personalized Therapy in Newly Diagnosed MM: Induction, Consolidation, and Maintenance Therapy
  • CME
  • CE

International myeloma experts—Brian G.M. Durie, MD; Shaji Kumar, MD; and Philippe Moreau, MD—discuss current treatment options for patients with newly diagnosed multiple myeloma and explore novel approaches now in clinical trials.
Brian G.M. Durie, MD
Program Director
Shaji Kumar, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesús F. San-Miguel, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 24, 2019 Expiration: April 23, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data along with risk assessment, comorbidities, and patient age/fitness
  • Identify ongoing trials of next-generation novel targeted agents, antibodies, and immunotherapies to aid referral of patients with multiple myeloma for study participation

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Produced in collaboration with
IMF Logo
This activity is supported by educational grants from
AbbVie
Amgen
Bristol-Myers Squibb
Celgene Corporation
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene, Johnson & Johnson, and Takeda.

Faculty

Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has served as a consultant for (paid to his institution) for AbbVie, Amgen, Celgene, Dr. Reddy’s Laboratory, Genentech, Janssen, Kite, MedImmune, Merck, Oncopeptides, and Takeda and has received funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda.
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no real or apparent conflicts of interest to report.
Philippe Moreau, MD

Professor of Clinical Hematology
Head,
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, and Takeda.
Jesús F. San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has reported that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Roche, Sanofi, and Takeda.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
Bing-e Xu, PhD

Scientific Director

Bing-e Xu, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no real or apparent conflicts of interest to report
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist both from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Goal

The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with myeloma.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Clinical Care Options, LLC, and International Myeloma Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

1.0 contact hour may be earned for successful completion of this activity.

Pharmacist Continuing Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-042-H01-P. This program is designated for up to 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit.

Type of Activity Knowledge

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2019, through April 23, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this Clinical Care Options (CCO) expert commentary, Jeff P. Sharman, MD, provides his thoughts on key studies in CLL and lymphomas that were presented at ASH 2019.

Jeff P. Sharman, MD Released: January 23, 2020

Expert commentary with practical insights on the recent FDA approval and use of acalabrutinib in CLL from Clinical Care Options (CCO)

Nicole Lamanna, MD Released: January 10, 2020

This archived CE-certified Clinical Care Options webcast presents optimal nursing strategies for the management of patients with multiple myeloma.

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Program Director
Joseph Tariman Headshot Joseph D. Tariman, PhD, RN, ANP-BC, FAAN
Program Director
Registered Nurses: 1.0 Nursing contact hour Released: January 6, 2020 Expiration: January 5, 2021

A summary slideset with a European perspective on highlights of key data in chronic lymphocytic leukemia and lymphomas from ASH 2019.

Released: December 23, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?